SK Bioscience Reports Operating Profit of 115 Billion KRW Last Year, Down 76% YoY
[Asia Economy Reporter Myunghwan Lee] SK Bioscience announced on the 8th that its consolidated operating profit for last year was tentatively estimated at 115 billion KRW, down 75.7% compared to the same period last year.
During the same period, sales decreased by 50.8% to 456.7 billion KRW, and net profit fell by 65.5% to 122.5 billion KRW.
SK Bioscience explained the cause of the poor performance as "the impact of decreased sales from contract manufacturing (CMO) and contract development and manufacturing (CDMO) of COVID-19 vaccines."
Hot Picks Today
If They Fail Next Year, Bonus Drops to 97 Million Won... A Closer Look at Samsung Electronics DS Division’s 600M vs 460M vs 160M Performance Bonuses
- Opening a Bank Account in Korea Is Too Difficult..."Over 150,000 Won in Notarization Fees Just for a Child's Account and Debit Card" [Foreigner K-Finance Status]②
- [Breaking] KOSPI Surges Over 8%, Breaks Through 7,800 Points
- Taiwan Unveils Bold Plan: Monthly Allowance for Children Under 18 to Tackle Low Birth Rate
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
On the same day, SK Bioscience resolved to establish the 'Songdo Global R&PD Center' and decided to make an investment of 325.7 billion KRW. This is the largest investment since its launch.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
!['WHO Declares International Public Health Emergency' Why the Untreatable 'Variant Ebola' Is More Deadly Than COVID-19 [Reading Science]](https://cwcontent.asiae.co.kr/asiaresize/307/2026052110164072055_1779326201.png)
!["Please Help Us": How Much Do Those Bowing 90 Degrees These Days Actually Earn? [Data Pick]](https://cwcontent.asiae.co.kr/asiaresize/307/2026052010120870131_1779239528.png)
